It has been confirmed that Osang Healthcare received preliminary approval for listing from the Korea Exchange on November 30.

Osang Healthcare, a subsidiary of Kosdaq-listed Osang jaiel, is a company specializing in in vitro diagnostics, and its predecessor was Infopia, which was established in 1996. Infopia became the first domestic company to receive approval from the U.S. Food and Drug Administration (FDA) for a personal blood glucose meter in 2003 and listed on the KOSDAQ market in June 2007. However, following the sale of management rights by the founder, issues of embezzlement and breach of trust by the acquirer arose, leading to the suspension of stock trading and placing the company on the brink of collapse. At this point, it was acquired by the Osang Group.

Full article : Osang Healthcare passes preliminary review for KOSDAQ listing